PepLib
Latest round
- Series C
Last raised
- May 2026
Total raised
- $107M
Investors
- 19
About PepLib
, trading as PepLib, specializes in peptide drug development. The company has pursued strategic investments to enhance its product offerings. The company specializes in the development and provision of innovative biopharmaceutical solutions, focusing on peptide-based drug discovery. Its core offerings include proprietary pipelines for peptide therapeutics, the PV2 DNA Polymerase, the 1402 Quick Cloning Kit, and various cell lines. These products assist pharmaceutical companies and research institutions in drug discovery and development, primarily across North America and Europe. The revenue model of the company is based on direct sales and partnerships with pharmaceutical and research entities. Transactions are facilitated through contracts for supplying flagship products, such as the PV2 DNA Polymerase and the 1402 Quick Cloning Kit, allowing clients to place bulk orders based on their research needs. In the future, the company will continue to focus on cutting-edge peptide drug technologies, accelerate the clinical and commercialization process of its core pipeline, and strive to bring more groundbreaking treatment options to patients worldwide as soon as possible.
Who invested in PepLib
19 investors across 4 rounds
See all investors in PepLib
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about PepLib
Who invested in PepLib?
PepLib has 19 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has PepLib raised?
PepLib has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did PepLib last raise money?
PepLib's most recent round on record is a Series C, in May 2026.
What does PepLib do?
, trading as PepLib, specializes in peptide drug development.
Where is PepLib headquartered?
PepLib is headquartered in Zhuzhou, China.
Which VCs invest in companies like PepLib?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at PepLib's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like PepLib? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.